Understanding Availability of Eylea Biosimilars
The landscape of ophthalmic treatments is evolving with the introduction of Eylea biosimilars, such as Yesafili and Opuviz, which offer cost-effective options for conditions like AMD and diabetic retinopathy. Legal hurdles and market dynamics shape their availability, emphasizing the importance of understanding these alternatives to enhance treatment accessibility and choice for patients and providers. Understanding […]
3 minute read